ETX-197
- Generic Name
- ETX-197
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1
Recruiting
- Conditions
- Breast CancerSmall Cell Lung CancerOvarian CancerGastric CancerHormone-receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerAdvanced Solid TumorEndometrial CancerProstate CancerTNBC - Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 218
- Registration Number
- NCT06257264
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇺🇸Hoag Memorial Presbyterian, Newport Beach, California, United States
🇺🇸Florida Cancer Specialists and Research Institute, Lake Mary, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath